Drug intelligence / Profile preview

atenolol + chlorthalidone

Development stage
Approved
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

**Atenolol + chlorthalidone** is an oral combination medication used primarily to treat high blood pressure (hypertension)[1][2][3][4][5][6][7]. It consists of two active components: - **Atenolol:** a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate and cardiac workload by blocking catecholamine action on beta-1 receptors in the heart[1][2][4][5]. - **Chlorthalidone:** a thiazide-like diuretic that acts on the kidneys to increase sodium and water excretion, lowering blood pressure by reducing plasma volume[1][2][4][5]. The combination's antihypertensive effects are additive, with no mutual interference in bioavailability[2]. It is usually reserved for patients already stabilized on the individual agents and not recommended as initial therapy[1]. Atenolol + chlorthalidone is available as tablets in various strengths, such as 50 mg/25 mg and 100 mg/25 mg[2][5]. Common side effects include gastrointestinal upset, dizziness, gout, and electrolyte disturbances. Serious adverse reactions may include liver dysfunction, pancreatitis, severe bradycardia, and psychosis[1][2][5].

Brand names
Tenoretic
Other names
co-tenidone
02

Targets

ADRB1 (β1)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on atenolol + chlorthalidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atenolol + chlorthalidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call